Every Form 4 that Cvrx, Inc. (CVRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CVRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVRX filings page.
CVRx, Inc. chief operating officer Brent Binkowski purchased 26,223 shares of common stock on August 13, 2026 in open-market or private transactions at a weighted average price of $2.9147 per share, with individual trade prices ranging from $2.87 to $2.96. Following these purchases, he directly holds 56,514 shares of CVRx common stock.
CVRx, Inc. chief operating officer Brent Binkowski reported a mandated sale of 1,309 shares of common stock on August 12, 2026. The shares were sold in a sell-to-cover transaction to satisfy tax withholding obligations at a weighted average price of $2.5502 per share, with individual prices between $2.55 and $2.564. Following this transaction, Binkowski directly holds 30,291 shares of CVRx common stock. The transaction is affirmed as made under a Rule 10b5-1 trading plan.
CVRx, Inc. director Kirk G. Nielsen reported routine equity awards. He received 8,720 shares of common stock as a grant at $0.00 per share and a stock option for 11,182 shares of common stock at an exercise price of $5.43 per share, expiring on June 1, 2036. The option vests on the earlier of June 1, 2027 or the company’s 2027 annual stockholders’ meeting. The filing also shows 1,910,134 common shares held indirectly through Vensana Capital I, L.P., where Nielsen shares voting and dispositive power but disclaims beneficial ownership beyond his pecuniary interest.
CVRx, Inc. director Mudit K. Jain reported equity compensation grants. He received 8,720 shares of Common Stock at no cost, bringing his direct holdings to 14,370 shares. He was also granted a stock option for 11,182 shares at an exercise price of $5.43 per share, expiring on June 1, 2036. The option vests on the earlier of June 1, 2027 or the company’s 2027 annual stockholder meeting. Separately, 980,183 shares are held indirectly by Treo Ventures I, L.P., where Jain is the general partner and shares voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
CVRx, Inc. director Joseph P. Slattery reported compensation-related equity grants. He received 8,720 shares of Common Stock at no cost and a stock option for 11,182 shares with an exercise price of $5.43 per share, expiring on June 1, 2036. The option vests on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders. After these grants, Slattery directly holds 39,365 Common shares. These are awards, not open-market purchases or sales.
CVRx, Inc. director Mitch C. Hill received equity compensation in the form of common shares and stock options. He was granted 8,720 shares of Common Stock at no cost, leaving him with 8,720 common shares held directly after the award. He also received a stock option for 11,182 shares of Common Stock at an exercise price of $5.43 per share, expiring on June 1, 2036. According to the footnote, this award vests on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders, indicating a long-term, service-based incentive rather than an open-market purchase or sale.
CVRx, Inc. director Kevin J. Ballinger reported receiving equity compensation consisting of common shares and stock options. He was granted 8,720 shares of Common Stock at no purchase price, bringing his direct common share holdings to 8,720 shares.
He was also granted a stock option for 11,182 shares of Common Stock at an exercise price of $5.43 per share, expiring on June 1, 2036. According to the footnote, this award vests on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders.
CVRx, Inc. director Martha Shadan reported equity awards that increase her stake in the company. She received 8,720 shares of Common Stock as a stock grant at no cost, bringing her direct Common Stock holdings to 8,720 shares.
She was also granted stock options for 11,182 shares of Common Stock at an exercise price of $5.43 per share, expiring on June 1, 2036. According to the footnote, these options vest on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders. These compensation-related awards are not open-market purchases or sales.
A director of CVRx, Inc. received equity awards consisting of 29,005 shares of Common Stock and stock options covering 36,252 shares on June 1, 2026 as compensation.
The options have an exercise price of $5.43 per share, are exercisable for 36,252 shares of Common Stock, and expire on June 1, 2036. According to the vesting terms, one-third of the shares subject to these awards vest on each annual anniversary of the grant date. Following these awards, the director directly holds 29,005 shares of Common Stock and options on 36,252 shares.
CVRx, Inc. reported that Chief Medical Officer Philip B. Adamson received new equity awards and completed a small share sale tied to tax withholding. On February 27, 2026, he was granted stock options for 62,000 shares of common stock at an exercise price of $8.16 per share, expiring on February 26, 2036, along with 41,000 restricted stock units. The restricted stock units vest 25% on each annual anniversary of the grant date, and the options vest 25% on February 27, 2027 with the remainder vesting monthly thereafter. On March 2, 2026, he sold 1,262 shares of common stock at a weighted average price of about $7.90 per share in multiple trades between $7.90 and $8.00, a sale that was mandated by the award agreement to satisfy tax withholding obligations through a sell-to-cover transaction. Following these transactions, he directly held 61,578 common shares.
Morrison Gregory reported acquisition or exercise transactions in this Form 4 filing.
CVRx, Inc. reported that Chief Human Resources Officer Gregory Morrison received equity awards on March 2, 2026. He was granted 154,500 stock options and 34,000 shares of common stock at no cost. The common stock represents restricted stock units vesting 25% annually, while the options vest 25% on March 2, 2027 and monthly thereafter.
CVRx, Inc. president and CEO Kevin Hykes reported both an equity award and a small tax-related sale. He received a grant of 238,000 stock options and 159,000 restricted shares, which vest over several years. To cover tax withholding from these awards, he sold 7,763 common shares at a weighted average price of $7.9027 per share in mandated sell-to-cover transactions. After these trades, he directly owned 284,237 common shares.
CVRx, Inc. Chief Marketing & Strategy Officer Paul Verrastro reported a mix of equity grants and a small sale. On February 27, 2026, he acquired 45,000 shares of common stock as restricted stock units and a 67,000-share stock option grant, both at no cost.
The restricted stock units vest 25% on each annual anniversary of the grant date, while the option vests 25% on February 27, 2027 and then monthly in equal installments. On March 2, 2026, he sold 1,284 shares of common stock at a weighted average price of $7.9021 per share, in transactions ranging from $7.90 to $7.98, to satisfy tax withholding obligations through a mandated sell-to-cover transaction. Following the sale, he directly held 60,551 shares of common stock and 67,000 stock options.
CVRx, Inc. chief financial officer Jared Oasheim reported a mix of equity grants and a small mandated share sale. He received a grant of 91,000 stock options at an exercise price of $0.0000 per share, vesting 25% on February 27, 2027 and then monthly thereafter. He was also granted 61,000 shares of common stock in the form of restricted stock units that vest 25% on each annual anniversary of the grant date. To cover tax withholding obligations from these awards, he sold 1,744 shares of common stock in an open-market sell-to-cover transaction on March 2, 2026 at a weighted-average price of $7.9022 per share, with individual sale prices ranging from $7.90 to $7.9831. After these transactions, he directly held 96,703 shares of common stock.
CVRx, Inc. Chief Revenue Officer John Robert Allen reported a mix of stock sales and awards. He sold 3,964 shares of common stock in an open-market transaction at a weighted average price of $7.9025 per share to cover tax withholding obligations from equity awards. He also received a grant of 35,000 restricted stock units and 52,000 stock options, both vesting over several years starting on February 27, 2027, increasing his long-term equity exposure to the company.
CVRx, Inc. chief operating officer Brent Binkowski reported equity awards on February 27, 2026. He received 23,000 stock options with an exercise price of $0.00 per share and a separate grant of 15,000 shares of common stock, both classified as awards rather than open-market purchases.
The 15,000-share common stock grant consists of restricted stock units that vest in four equal annual installments of 25% on each anniversary of the grant date. The 23,000-stock-option award vests as to 25% of the shares on February 27, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. After these transactions, Binkowski directly owned 31,600 shares of common stock, according to the filing.
CVRx director-associated entity reports open-market share purchase. Treo Ventures I, L.P., an entity for which director Mudit K. Jain is the general partner, bought 46,800 shares of CVRx common stock on February 20, 2026 at a weighted average price of $6.3588 per share, with individual prices ranging from $5.8500 to $6.3868. Jain also directly holds 5,650 common shares after these transactions.
CVRx, Inc. director Mudit K. Jain reported an open-market purchase of 600 shares of common stock at a weighted average price of $4.6417 per share on February 18, 2026. Following this transaction, he directly holds 5,650 common shares.
In addition, 933,383 common shares are held indirectly through Treo Ventures I, L.P., where Jain is the general partner and shares voting and dispositive power. He disclaims beneficial ownership of these indirectly held shares except to the extent of his pecuniary interest.